

533 Rec'd PCT/PTO 21 AUG 2001


FORM PTO-1350 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 227-142
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 09/913954 Unknown
INTERNATIONAL APPLICATION NO. PCT/FI00/00140	INTERNATIONAL FILING DATE 22 February 2000	PRIORITY DATE CLAIMED 22 February 1999
TITLE OF INVENTION DIAGNOSTIC AND SCREENING METHOD		
APPLICANT(S) FOR DO/EO/US JACOBS et al. <i>HOWARD et al.</i>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
- ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
- A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - ☐ is attached hereto (required only if not communicated by the International Bureau).
 - ☒ has been communicated by the International Bureau.
 - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - ☐ is attached hereto.
 - ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - ☐ are attached hereto (required only if not communicated by the International Bureau).
 - ☐ have been communicated by the International Bureau.
 - ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - ☐ have not been made and will not be made.
- ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 To 20 below concern document(s) or information included:

- ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- ☒ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
- ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- ☐ Other items or information.

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.51) 09/1913954		INTERNATIONAL APPLICATION NO. PCT/FI00/00140		ATTORNEY'S DOCKET NUMBER 227-142	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5): -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$690.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	14	-20 =	0	X	\$18.00
Independent Claims	6	-3 =	3	X	\$80.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					\$270.00
TOTAL OF ABOVE CALCULATIONS =				\$	1230.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					615.00
SUBTOTAL =				\$	615.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					0.00
TOTAL NATIONAL FEE =				\$	615.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				+	\$ 0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)				+	\$ 0.00
TOTAL FEES ENCLOSED =				\$	615.00
				Amount to be:	
				refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$615.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000					
				 SIGNATURE	
				Arthur R. Crawford NAME	
				25,327 REGISTRATION NUMBER	
				August 21, 2001 Date	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

JACOBS et al.

Atty. Ref.: 227-142

Serial No. Unknown

Group:

Filed: August 21, 2001

Examiner:

For: DIAGNOSTIC AND SCREENING METHOD

* * * * *

August 21, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for examination,
please amend the application as follows:

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously
presented. A copy of the amended claims showing current revisions is attached.

3. (Amended) A method of claim 1, **characterized** in that the mutation or mutations are located in the trinucleotide (CAG) microsatellite repeat of the *POLG* gene.
5. (Amended) A method of claim 1, **characterized** in that the mutation or mutations are located in or near a coding region of the *POLG* gene.
6. (Amended) A method of claim 1, **characterized** in that one mutation or mutations are located in one allele of the *POLG* gene in the trinucleotide (CAG) microsatellite repeat and

another mutation or other mutations in the other allele of the mutant *POLG* gene in or near a coding region of the gene.

7. (Amended) A method of claim 1, **characterized** in that the detection of the mutation is performed using a gene-technological method.

9. (Amended) A method of claim 1, **characterized** in that the detection of the mutation or mutations is performed using an immunological method, such as a Western analysis, immunohistology or immunoassay, for characterization of a mutant gene or gene product.

REMARKS


The above amendments are made to place the claims in a more traditional format.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Arthur R. Crawford
Reg. No. 25,327

ARC:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

3. (Amended) A method of claim 1-~~or~~2, **characterized** in that the mutation or mutations are located in the trinucleotide (CAG) microsatellite repeat of the *POLG* gene.

5. (Amended) A method of claim 1-~~or~~2, **characterized** in that the mutation or mutations are located in or near a coding region of the *POLG* gene.

6. (Amended) A method of claim 1-~~or~~2, **characterized** in that one mutation or mutations are located in one allele of the *POLG* gene in the trinucleotide (CAG) microsatellite repeat and another mutation or other mutations in the other allele of the mutant *POLG* gene in or near a coding region of the gene.

7. (Amended) A method of ~~any one of~~ claims 1-~~to~~6, **characterized** in that the detection of the mutation is performed using a gene-technological method.

9. (Amended) A method of ~~any one of~~ claims 1-~~to~~6, **characterized** in that the detection of the mutation or mutations is performed using an immunological method, such as a Western analysis, immunohistology or immunoassay, for characterization of a mutant gene or gene product.

09/913954

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

JACOBS et al.

Appln. No. 09/913,954

Filed: August 21, 2001

FOR: DIAGNOSTIC AND SCREENING METHOD FOR MALE INFERTILITY



Atty. Ref: 227-142

Group Art Unit: Not Known

Examiner: Not Known

* * *

PRELIMINARY AMENDMENT AND SUBMISSION OF SEQUENCE LISTING

December 4, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements mailed on October 17, 2001, entry and consideration of the following amendments and remarks are requested.

IN THE TITLE

Kindly replace the present title with the following:

DIAGNOSTIC AND SCREENING METHOD FOR MALE INFERTILITY

IN THE SPECIFICATION

Page 1 after the title, kindly enter the following new paragraph.

This is a national stage application under 35 U.S.C. 371 of PCT/FI00/00140, filed February 22, 2000, now abandoned.

IN THE ABSTRACT

Kindly enter the attached abstract of the disclosure.

IN THE SEQUENCE LISTING

Kindly enter the attached substitute paper and original computer readable forms of the Sequence Listing in lieu of the Sequence Listing submitted on August 21, 2001.

REMARKS

Claims 1-14 are pending.

Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the requirement to comply with the Sequence Rules 37 CFR § 1.821 et seq. The attached substitute paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. Prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.

No new matter is added by the insertion of the priority claim in the specification and the original abstract of the disclosure on a separate sheet.


The inventors' declaration is submitted herewith. Form PCT/IB/306 shows that the assignee was changed from Ancibio Ltd. to Licentia Oy.

Having fully responded to the Notification, Applicants submit the requirements for a patent application have been satisfied and earnestly solicit an early examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



APPENDIX

MARKED-UP VERSION TO SHOW CHANGES

IN THE TITLE

The title is amended as follows.

DIAGNOSTIC AND SCREENING METHOD FOR MALE INFERTILITY

IN THE SPECIFICATION

The following new paragraph is added on page 1 after the title:

This is a national stage application under 35 U.S.C. 371 of PCT/FI00/00140, filed February 22, 2000, now abandoned.

IN THE ABSTRACT

The abstract of the disclosure is attached.

IN THE SEQUENCE LISTING

The substitute paper and original computer readable copies of the Sequence Listing are attached.



ABSTRACT OF THE DISCLOSURE

The present invention relates to a novel diagnostic method for the detection of infertility in males. In particular, the present invention relates to a diagnostic method for detecting the presence or absence of a mutation or mutations in the *POLG* gene encoding mitochondrial DNA polymerase in a biological sample. The invention relates also to the use of a mutant *POLG* gene in the detection of infertility in males and in the screening of human populations for the presence of such mutation or mutations as a predictive test for male infertility. The invention also relates to the use of the *POLG* gene as an indicator of other pathological conditions associated with or related to male infertility, including those manifesting in women.

094944-1

DIAGNOSTIC AND SCREENING METHOD

FIELD OF THE INVENTION

The present invention relates to a novel diagnostic method for the detection of infertility in males. In particular, the present invention relates to a
5 diagnostic method for detecting the presence or absence of a mutation or mutations in the *POLG* gene in a biological sample. The invention relates also to the use of a mutant *POLG* gene in the detection of infertility in males and in the screening of human populations for the presence of such mutation or mu-
10 tations as a predictive test for male infertility. The present invention further re- lates to the use of the *POLG* gene as an indicator of other pathological condi- tions associated with or related to male infertility, including those manifesting in women.

BACKGROUND OF THE INVENTION

Fertility problems have manifested increasingly in western countries
15 due to a variety of social causes. For example, young couples delay their de- cision to establish a family for reasons of education and career, and tend to plan for a smaller family size due to the increasing priority placed upon quality of life. Environmental and lifestyle factors may also play a part in revealing an underlying subfertility due primarily to other causes. For many couples, pro-
20 longed attempts to become pregnant end in failure, resulting in their seeking assistance from an infertility clinic. This decision is often taken long past the time when they initially would have hoped to start a family. People are under- standably reluctant to take a step that may seem humiliating. Such delays, to- gether with the attendant stress, anguish and shame, can have a profoundly
25 destructive effect on relationships and on quality of life generally.

Infertility can result from a great variety of causes, including ana- tomical, developmental, infectious and toxicological factors. The majority of cases can be attributed wholly or predominantly to one or other partner, with roughly equal numbers of cases of male and female factor infertility. In both
30 instances, however, the primary cause is almost certainly genetic. Estimates of the true population prevalence of infertility vary, but are generally accepted to be in the range of 2 to 5%. This is, therefore, one of the commonest human genetic disorders.

Male infertility can manifest as reduced quantity (oligozoospermia)
35 or total lack (azoospermia) of sperm, reduced quantity of motile sperm

(asthenozoospermia) or morphologically abnormal sperm (teratozoospermia). These categories are not exclusive, since many infertile males appear to fall into more than one such class. Microscopic, cytological and biochemical methods are presently available for the determination of these defects. However, actual measurements can be highly variable, even for a single individual between samplings. Frequently, moreover, no actual cause for male infertility can be found. This can cause additional costs arising from the need for further clinical examinations. Selecting an appropriate method of assisted reproduction is often a haphazard and costly matter, with no guarantee of eventual success. All these difficulties and delays can place severe, additional strains on relationships. Additional means for the early detection or prediction of infertility, in particular male infertility are thus needed. Early detection of male infertility would save both money and human stress and would allow appropriate counselling or assisted reproduction to be offered to a significant population of individuals who would otherwise only discover their problem after it has caused severe damage to their quality of life.

Though it has been long suspected that male infertility in most cases is a genetic disorder, and furthermore that it is genetically heterogeneous (i.e. that many different genes are the underlying cause of the disorder in different individuals), little information has emerged relating specific genetic defects and male infertility. The two known genetic causes of male infertility are the 'cystic fibrosis' mutations in the *CFTR* gene, part of a clearly recognizable clinical syndrome affecting approximately one person in 1500 [see, e.g. Lissens, W. and Liebaers, I. Baillieres Clinical Obstetrics and Gynaecology 11 (1997) 797-817; Schnedl, W. *et al.*, Wiener Klinische Wochenschrift 103 (1991) 29-33] and a deletion on the Y chromosome, that leads to complete azoospermia, and is found in approximately 1 to 2% of infertile males in this category [Elliott, D.J. and Cooke, H.J. BioEssays 19 (1997) 801-809]. The supposed genetic cause of male infertility in the vast majority of cases has thus far remained unknown.

Since spermatozoa are heavily dependent on respiratory energy for motility, impaired energy metabolism, whether in mature spermatozoa or at earlier stages of male germ cell differentiation, is a long hypothesized mechanism contributing to infertility. Defects in mitochondrial function [Johns, J.C.S. *et al.*, Nat Med 3 (1997) 124-125], possibly associated with mtDNA lesions [Kao, S.H. *et al.*, Mol Hum Reproduction 4 (1998) 657-666; Lestienne P. *et al.*,

Mol Hum Reproduction 3 (1997) 811-814], have been reported in sperm samples from infertile males, and sperm motility appears to be correlated with mitochondrial respiratory activity [Ruiz Pesini, E. *et al.*, Clin Chem 44 (1998) 1616-1620] and membrane potential [Troiano, L. *et al.*, Exp Cell Res 241 (1998) 384-393]. However, no relationship between a specific mitochondrial gene and male infertility has been disclosed or even suggested.

SHORT DESCRIPTION OF THE INVENTION

It has now, surprisingly, been discovered that the frequency of a mutant genotype in the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase (DNA polymerase γ) is significantly increased in groups of infertile males. Specifically, the mutant genotype has been located in the area of the trinucleotide (CAG) microsatellite repeat of the *POLG* gene within the N-terminal region of the coding sequence. While the normal *POLG* gene contains 10 consecutive, glutamine encoding CAG codons, followed by a single CAA and two further CAGs, at least one allele with an altered CAG repeat-length in the *POLG* gene is found in a large population of infertile men.

The *POLG* mutations described in the present application represent the first significant step in efforts of elucidating the genetic nature of male infertility and provide novel means of diagnosis thereof.

An object of the invention is thus to provide a non-invasive, non-intrusive diagnostic method that is useful in identifying, detecting and characterizing male infertility in the large fraction of cases where its causes remain unsolved.

A second object is to provide a simple screening test of strong predictive value, in order to identify in advance those individuals who will require reproductive counselling and assistance. Such information will greatly enhance the expected quality of life of those who suffer from this disorder.

The present invention relates to a new method for the diagnosis of male infertility by detecting the presence or absence of a mutation or mutations in the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase in a biological sample.

The present invention also relates to the use of a mutant form of the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase for the diagnosis of male infertility.

The present invention also relates to the use of a mutant form of the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase

as a diagnostic agent.

The present invention further relates to diagnostic kits containing suitable reagents to detect a mutant form of the *POLG* gene or the normal *POLG* gene.

- 5 The present invention further relates to the use of the *POLG* gene as an indicator of other pathological conditions associated with or related to male infertility, including those manifesting in women.

DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the genotype data of Table 2 as a bar chart.

10 DETAILED DESCRIPTION OF THE INVENTION

- Microsatellite sequences (short sequences consisting of consecutive runs of a simple repeated element, such as a di- or trinucleotide) are well established sources of genetic polymorphism, exhibiting significant levels of length variation in the many genetic loci where they are found. This reflects the
- 15 fact that they are inherently less stable than other sequences during, for example, DNA replication or repair, where slippage mis-pairing events may increase or decrease the number of re-iterated units. Many such sequences are found within the human genome, and are usually located outside of coding regions, where they have little consequence for phenotype. In some instances,
- 20 however, they are located within or adjacent to coding DNA. In these cases, large expansions of the number of repeat units can have a profound effect, leading to loss or gain of genetic function and a resulting pathological phenotype. Instability at trinucleotide repeats is already known to be associated with various human disorders, including, for example, Huntington's disease (HD),
- 25 myotonic dystrophy (DM), and several forms of spinocerebellar atrophy (e.g. SCAI). Other, more subtle variations at trinucleotide microsatellites can also affect phenotype, and the association described herein, between male infertility and variation in the CAG trinucleotide tract of the *POLG* gene, encoding the catalytic subunit of mitochondrial DNA polymerase, falls into such a category.

- 30 Rovio, A. *et al.* studied the frequency of different repeat-length alleles of the *POLG* gene in control populations, as well as in groups of patients suffering from recognized mitochondrial disorders (Eur J Hum Genet, 1999 in press). The predominant allele of 10 CAG repeats was found at a very similar frequency (approximately 88%) in both Finnish and ethnically mixed popula-
- 35 tion samples, with homozygosity close to the equilibrium prediction of 80%.

Other alleles of between 5 and 13 repeat units were detected, but no larger, expanded alleles were found. Patients with a variety of molecular lesions in mtDNA showed no differences in *POLG* trinucleotide repeat-length distribution from controls. The authors concluded that their findings rule out *POLG* repeat expansion as a common pathogenic mechanism in disorders characterized by mitochondrial genome instability.

The present invention is based on studies that were designed to test a hypothesis that this gene, encoding a major component of the machinery of mitochondrial DNA maintenance, is involved in infertility, via impaired energy metabolism of spermatozoa. The *POLG* gene encodes a protein of approximately 130 kDa and has been mapped to the region of chromosome 15q24-15q26 [Walker, R.L. *et al.*, Genomics 40 (1997) 376-378; Ropp, P.A. and Copeland, W.C., Genomics 36 (1996) 449-458; Zullo, S.J. *et al.*, Cytogenet Cell Genet 78 (1997) 281-284].

For PCR analysis, nested primers flanking the *POLG* CAG repeat were designed, based on a region of the coding sequence of *POLG* (see sequence id. no. 1). The primers amplified the predicted fragments from genomic DNA, as verified by direct sequencing. Testing against the monochromosomal interspecies hybrid and Genebridge 4 radiation hybrid panels [Gyapay, G. *et al.*, Hum Mol Genet 5 (1996) 339-346] confirmed that they detected only the expected gene sequence from chromosome 15q, and not a pseudogene. The 5' primer (also designated mip51) was also found to generate the predicted products, using other, more downstream 3' primers from the same exon of the *POLG* gene. Using these primers and sperm DNA from individuals in whom azoospermia was excluded, the PCR analysis showed that 9 out of 99 male infertiles were homozygous for absence of the normal, 10 repeat-unit allele. Thus approximately 10% of infertile males, whose infertility is not clearly attributable to known causes, and excluding cases of azoospermia, completely lacked the common *POLG* allele, having 10 consecutive CAG codons. Instead they possessed two alleles with a different number of CAG repeats. No instances of this genotype were found in sperm DNA from 98 fertile males. The association is highly significant based on two different statistical tests (the z-test for percentages, as well as Poisson probabilities). The homozygous mutant genotype was found in only 2 of over 250 healthy controls collected without regard to gender or fertility.

Male infertiles also showed a higher frequency of heterozygosity

than found amongst fertile males or in the general population. Some 35% of infertile males, compared with only about 20% in the fertile or unselected population, were heterozygous at the *POLG* CAG repeat, i.e. possessed one copy of the wild-type or normal allele with 10 repeats, and one other copy.

- 5 These figures strongly indicate that many of the 35% of infertiles who are heterozygotes are, in fact, compound heterozygotes, i.e. that the allele of the *POLG* gene that is apparently wild-type or normal at the CAG repeat in fact carries a mutation elsewhere in the gene, such that both copies are defective, at least as regards the function that *POLG* performs in spermatogenesis that is
10 required for fertility.

PCR studies of *POLG* genotype frequencies in blood DNA from various categories of patients indicated that a mutation at this locus is not associated with azoospermia or with severe oligozoospermia, but is found in individuals with a range of sperm quality defects.

- 15 Also fluorescent PCR using custom primers was used to genotype all individuals in the study for *POLG* CAG repeat length, as summarized in Table 2. Semen DNA from a minority (approx. 15%) of male infertiles yielded no clear signal and these were excluded from consideration. Approximately 10% of individuals lacked the normal allele. By contrast, this normal allele was present in all 98 fertile males studied. The normal allele was also absent in only
20 one out of 118 healthy male controls, which had not been selected on the basis of fertility, in addition to the 250 controls studied previously without regard to gender or fertility.

- Given that the combined frequencies of mutant alleles (i.e. those
25 having any number of repeats other than 10) revealed in the population survey of Rovio, A. *et al.* (supra) was 0.12, the homozygous mutant genotype is expected to be found in approximately 1.5% of randomly selected individuals, based on standard Hardy-Weinberg predictions (see Table 2). The above data indicate that it was found in the general population slightly below expectation
30 (0.8%, i.e. 2 out of 252), although this deviation is not statistically significant. By contrast, finding the homozygous mutant genotype by chance in 9 out of 99 individuals is exceedingly unlikely, assuming that the previously measured allele frequencies are representative. The association is significant ($p < 0.01$) based on a z-test for percentages (comparing fertile and infertile groups), or
35 using Poisson statistics (assuming a mean population frequency of the homozygous mutant genotype of 1.5%).

WO 00/50629

PCT/FI00/00140

7

Many different alleles and combinations thereof were found in individuals lacking the common allele (Table 1). This indicates that it is the absence of the normal allele, rather than the presence of a particular alternate allele, that is associated with the phenotype. All alleles found in infertiles were also found in controls. The frequencies, relative to one another, of the various mutant alleles found amongst infertiles were also similar to those found in the general population. The different profiles of *POLG* genotypes found in sperm DNA from fertile and infertile males, compared with controls, is illustrated in Figure 1. 35 out of 99 (i.e. 35%) of infertiles were heterozygotes, carrying just one copy of the normal allele.

This is well above expectation (21%), based on the measured allele frequencies in the overall population, or compared with the fertile control group (18%). Importantly, some of these could represent compound heterozygotes, with a second mutation mapping elsewhere in the gene than within the CAG repeat of the coding region of the gene.

In order to establish the type of infertility associated with *POLG* genotype, blood DNA was studied from two larger groups of patients, who included a high proportion of azoospermic individuals and those with severe oligozoospermia (sperm concentration $< 5 \times 10^6$ /ml), as well as individuals with only a mild abnormality of sperm concentration, motility and/or morphology. Sperm DNA was also analyzed from a further set of patients, for whom extensive phenotypic data were available, and which consisted of cases of 'pure asthenozoospermia', with sperm concentrations well into the normal range (generally $> 100 \times 10^6$ /ml).

Cases lacking clear results of sperm analysis were excluded, as were those where clinical or karyotypic examination clearly indicated an established hormonal, developmental or traumatic etiology of their infertility. The azoospermic and severe oligozoospermic patients were considered separately from those having sperm concentrations of 5×10^6 /ml or greater.

Out of 62 azoospermic and 73 severe oligozoospermic individuals, no cases of homozygous absence of the normal allele were detected. The frequency of heterozygotes in these groups (30%) was, however, slightly above the population average. By contrast, 8 out of the 113 with infertility of unknown etiology, and having measured sperm concentrations of 5×10^6 /ml or greater, lacked the normal allele.

Individuals homozygous for the absence of the normal allele were

found in every category of sperm quality defect (sperm number, motility or morphology, or any combination). Most, however, were at or below at least two of the thresholds commonly used to define oligozoospermia (20×10^6 sperm/ml), asthenozoospermia (50% motile sperm) and teratozoospermia (10% morphologically normal spermatozoa). However, no mutant genotype was found in semen DNAs from the 56 patients with 'pure asthenozoospermia'. It is concluded that the mutant *POLG* genotype is associated with a general impairment in sperm quality and/or number, but neither with the complete or almost complete absence of spermatozoa, nor with a motility defect as such. The simplest interpretation is that cell division or differentiation is impaired, leading to a low production of normal spermatozoa.

The above data clearly indicate that *POLG* alleles other than the normal one of 10 repeat units are deleterious to sperm function or differentiation, but have little or no effect on other tissues. Polyglutamine tracts are commonly regarded as interfaces for protein-protein interactions, hence it is possible that a sperm-specific protein interacts with this region of the polypeptide. Other possibilities are that repeat-length variants are inherently unstable, poorly targeted to mitochondria, or enzymatically defective, all of which are testable. The many rounds of cell division during spermatogenesis, plus the necessity, for the creation of functional spermatozoa, of maintaining a genetically fit mitochondrial genome, argue that a sub-optimal mtDNA polymerase, whether by virtue of impaired fidelity, processivity, or some other defect, could result in the accumulation of mtDNA mutations and failure to complete differentiation.

Male infertility is certainly a genetically heterogeneous disorder [Sokol, R.Z., Curr Opinion Obst Gynaecol 7 (1995) 177-181]. The data of the present invention indicate that where there is no other obvious etiology, approximately 10% and perhaps as many as 20% of cases are associated with a mutant genotype at the *POLG* locus, excluding those where sperm count is negligible.

The measured frequency of mutant alleles in the population (approx. 0.12) means that approximately 1.5% of all males will lack the normal allele, and are predicted to be infertile or at least subfertile, based on these findings.

According to the diagnostic method of the present invention, the presence or absence of a mutation or mutations in the *POLG* gene can be

detected from a biological sample by any known detection method suitable for the purpose. Thus, the presence or absence of a mutation or mutations in the *POLG* gene can be detected from a biological sample by any known method for detecting gene copy number or expression, i.e. methods based on detecting the copy number of the gene (or DNA) and/or those based on detecting the gene expression products (mRNA or protein). Such methods are easily recognized by those skilled in the art and include the use of the polymerase chain reaction (PCR) or other thermal cycler-based DNA synthetic techniques in the presence of appropriate oligonucleotide primers specific for the *POLG* gene, molecular cloning in a plasmid or other suitable vector, detection of length variants in a DNA sample by agarose or polyacrylamide gel electrophoresis or any analogous technique, gel or capillary electrophoresis with automated detection and analysis of products tagged with a fluorescent or other label incorporated into the DNA, DNA sequence determination by any technique, heteroduplex-based and associated methods for detecting base mismatches or length variants, mass spectroscopy, chromatographic and other separation methods, Western analyses, immunohistochemistry, and other immunoassays, and any technique suitable for the detection and functional characterization of nucleic acid and protein which may be applied in mutational analysis. Preferable methods are those suitable for use in routine clinical laboratories, or which may eventually be developed in self-test kits.

In the diagnostic method of the invention, the biological sample can be any suitable tissue sample or body fluid, such as buccal smear (mouthwash), hair roots, semen, seminal plasma, whole blood, serum or plasma, or cultured cells derived from any biopsy. The biological sample can be, if necessary, pretreated in a suitable manner known to those skilled in the art, for the purposes of extraction of DNA in a form suitable for analysis.

The diagnostic kit of the present invention comprises reagents necessary for the detection of a mutation or mutations in the *POLG* gene. These reagents include specific antibodies, preferably monoclonal antibodies, capable of identifying the *POLG* gene or its gene products, other antibodies, primers, markers and/or standards that are needed for visualization or quantification as well as buffers, diluents, washing solutions and the like, commonly contained in a commercial reagent kit. Alternatively, the diagnostic kit of the present invention may comprise portions of the *POLG* gene or its functional variant or fragment, or other nucleic acid-derivative related to it, together with

suitable reagents, such as those listed above, needed for the detection of the mutation or mutations in the *POLG* gene.

The present invention provides an additional means for detecting and analyzing male infertility, and a means for predicting it, when carried out on adults, children, in infancy, *in utero* or during embryonic development.

The invention is now elucidated by the following non-limiting examples. The patients and controls used in the first example are as follows. Volunteers for the study, as authorized by the local ethical committee, were recruited from amongst male infertiles attending an infertility clinic in Oxford. Semen samples obtained by masturbation were stored frozen in liquid nitrogen for further study. Azoospermic individuals (approx. 20% of the total) were excluded, as were any for whom a clear, established etiology (hormonal, developmental, karyotypic or traumatic) could be found to account for their infertility. Semen was also collected from sperm donors, for use as fertile controls in the study. Semen or seminal plasma was also provided from similarly defined infertile males in Tampere, Finland, and from infertiles in Australia and Taiwan. Blood samples were provided from fertile and infertile males, as well as from unselected control males in Düsseldorf, Germany, and from male infertiles in Edinburgh, Scotland. Blood samples were also provided by otherwise healthy volunteers amongst laboratory personnel and associates, who were not screened for fertility.

Example 1

Genotyping at the *POLG* CAG repeat as a diagnostic test for male infertility

DNA was prepared from fresh or frozen sperm or seminal plasma as follows. 400 µl samples were micro-centrifuged at 13,000 rpm for 5 min and the pellets washed twice with phosphate buffered saline, pH 7.4 (PBS). Crude DNA was then extracted from the washed pellets by incubating with proteinase K as described by Reid, F.M. *et al.* [Hum Mutation 3 (1994) 243-247], followed by inactivation of the enzyme at 92°C for 10 minutes. Blood DNA was isolated by the same method, as described by Reid, F.M. *et al.*, *supra*. DNA can be obtained from other biological samples using essentially similar methods which are well known to those skilled in the art. Prior to all PCR analyses, the DNA extracts were microcentrifuged for 15 sec and 0.5 µl of clear lysate used as template. In any cases where signals were low or uninterpretable, PCR was repeated using 0.5 µl of the template DNA solution diluted to various extents in

order to reduce the concentration of contaminants that may inhibit DNA synthesis. More than 0.5 µl of template DNA solution may also be used, if sample concentration is judged to be too low.

Fluorescent PCR analysis of *POLG* genotype was carried out as follows. Nested oligonucleotides corresponding to regions of the N-terminal coding sequence of *POLG*, as indicated in the accompanying list of sequences, were purchased from Life Technologies (Paisley, Scotland) and DNA Technology (Aarhus, Denmark). One of the primers, mip51 (5' CCAGCTCCGTCCCCGCGTCCGACC 3'; sequence id. no. 2), was 5' prela-
beled with the fluorescent dye ROX (PerkinElmer) by the manufacturer, but other dyes of similar application can also be used.

Fluorescent PCR reactions used, at 0.2 mM each, ROX-labeled primer mip51 plus one downstream primer, unlabelled, either mip31 (5' GCTGCCCGCCCTCCGAGGATAGCAC 3'; sequence id. no. 3; generating a 126 bp PCR product from the wild-type allele, when used in combination with primer mip51), mip32 (5'CTCTCGAGAGCATCTGGATGTCCAATC 3'; sequence id. no. 4; generating a 165 bp PCR product from the wild-type allele, when used in combination with primer mip51) or mip33 (5'CTCGTGCGAGCCCTCTCGAGAGCAT 3'; sequence id. no. 5; generating a 176 bp PCR product from the wild-type allele, when used in combination with primer mip51). Reactions were carried out in 12.5 µl at 200 µM dNTPs (Pharmacia Biotech, Sweden), plus an appropriate quantity of a suitable thermostable DNA polymerase (0.15 units of Dynazyme, from Finnzymes, Espoo, Finland) in the manufacturer's buffer. Reactions comprised 30 cycles of denaturation for 1 min at 95°C, annealing for 45 sec at 62°C, and extension for 1 min at 72°C (a 5 min extension in final cycle). Products were diluted 1:10 in water, and samples containing 1 µl of diluted PCR product, 12 µl of deionized formamide and labelled DNA fragment size markers in the appropriate size range were added [e.g. 0.15 µl of Tamra Genescan350 DNA size standards (Perkin Elmer)], and samples were analyzed by capillary electrophoresis on a suitable electrophoresis/fluorescent analysis instrument, e.g. ABI 310 Genetic Analyzer (PerkinElmer), using the manufacturer's data collection and analysis software.

Samples giving ambiguous or low signals, or those giving a result indicative of a mutant genotype, were re-evaluated using a second downstream primer. In all analyses, a reaction using a template DNA sample previ-

ously demonstrated to contain only the wild-type *POLG* allele, as well as a reaction run without any added DNA, were run alongside as positive and negative controls, respectively.

The results showing the mutant *POLG* alleles of male infertiles are shown in Table 1.

Table 1

Mutant *POLG* alleles of infertile males

<i>POLG</i> repeat-length genotype	Number
11/11	8
11/12	5
11/9	3
9/12	2
11/13	1
9/9	1
8/11	1
8/12	1
6/12	1
Total	23

10

The PCR amplification and fluorescent analysis described enabled samples to be categorized as follows:

Class I – WILD-TYPE (or normal) HOMOZYGOTES: only a single allele was detected, as a clean peak of a size consistent with the presence of 10 consecutive copies of the CAG repeat.

Class II – MUTANT 'HOMOZYGOTES': one or two alleles were detected, both corresponding with length variants other than the wild-type allele of 10 CAG repeats. These individuals are compound heterozygotes at the *POLG* CAG repeat. However, since such individuals are homozygous for loss of the wild-type allele, they are placed in a different category from 'true' het-

erozygotes as defined below (Class III).

Class III – HETEROZYGOTES: two length alleles were detected, one corresponding with the wild-type allele (10 CAG repeats) and the other a different number.

- 5 Data for such an analysis are illustrated in Figure 1 and Tables 2 and 3, below. Controls were the combined sets collected previously from Finland, being a mixture of Finns plus other ethnic groups of both sexes, plus those from Germany (males only, no selection based on fertility). Infertiles and
10 fertiles indicated in Table 2 each represent pooled groups of individuals from Finland and England.

Table 2

***POLG* genotype frequencies detected in various fertile and infertile males (sperm), plus unselected controls (blood)**

Patients (COUNTRY)	Class I: wild-type homozygotes	Class II: mutant 'homozygotes'	Class III: het- erozygotes
Infertile males (FIN/ENG)	55 (56%)	9 (9%)	35 (35%)
Fertile Males (FIN/ENG)	80 (82%)	0 (0%)	18 (18%)
Total controls (FIN/ENG/D)	195 (77%)	2 (1%)	55 (22%)

Table 3

Frequency of 'mutant homozygotes' (Class II) in various groups of infertile males

Patients (COUNTRY, DNA SOURCE)	Total analysed	Class II: mutant 'homozygotes'
Azoospermia or severe oligozoospermia (sperm concentration < $5 \times 10^6/\text{ml}$) (D/SCO, blood)	135	0 (0%)
Pure asthenozoospermia (< 50% motile, normal sperm concentrations) (Taiwan, sperm)	55	0 (0%)
Combined sperm quality defect (2 or more of moderate oligozoospermia, as- thenozoospermia, and teratozoospermia) (D, blood)	113	8 (7%)

5

The analysis resolved the samples into the following groups in a clearly predictive manner, as follows.

(1) Genotype frequencies in the control group were very close to the equilibrium predictions based on overall population-based measurements of allele frequencies of 0.88 (wild-type, 10 CAG repeats) and 0.12 (all mutant alleles combined).

(2) No instances of 'mutant homozygotes' (Class II) were detected amongst fertile males.

(3) Approximately 9% of infertile males, excluding cases of azoospermia and severe oligospermia, fell into Class II.

(4) Heterozygotes (Class III) were found in all groups, but at a higher frequency in infertile than fertile males or controls.

The diagnostic and counselling implications of the test for *POLG* genotype that forms the subject of the present invention, and as proposed to be carried out, for example, in an infertility clinic, are as follows:

20

- (1) A result falling into Class II is an indicator of a specific type of male factor infertility, associated with *POLG* dysfunction. This genotype is never found in fertile males. Other clinical or biochemical investigations of both partners can essentially be dispensed with as unnecessary. Even in the absence of sperm quality data, it indicates that intra-uterine insemination and probably IVF are likely to fail, and that recourse to ICSI (intra-cytoplasmic sperm injection) is advisable.
- (2) A result falling into Class I does not exclude male factor infertility of other types, nor any other diagnosis.
- (3) A result falling into Class III is ambiguous, and warrants further genetic investigation of the *POLG* locus, as illustrated below (example 2).

Example 2

Complete analysis of the *POLG* gene as a diagnostic test for male infertility

Results from the type of analysis illustrated in Example 1 are necessarily ambiguous in the case of individuals who prove to be heterozygous at the *POLG* gene CAG repeat (i.e. who possess one copy of the wild-type, 10-repeat allele, plus one copy of some other length variant). In these cases, further investigation is warranted, in order to establish whether they represent cases of true heterozygotes (one fully functional, one mutant copy of the gene), as found amongst fertile males and controls, or whether they represent compound heterozygotes carrying one copy of the gene mutated within the *POLG* CAG repeat tract, and a second copy which has a pathological mutation elsewhere in the gene. The present invention thus covers not only the use of genotyping at the CAG repeat, but also the complete sequencing of the *POLG* gene as a diagnostic procedure for the determination of male infertility associated with *POLG* gene dysfunction, in cases where genotyping at the CAG repeat is insufficient to permit an unambiguous molecular diagnosis. Because such cases are expected to constitute up to half of all individuals with *POLG*-associated infertility, based on the observed frequencies of homo- and heterozygotes, i.e. given the excess number of heterozygotes amongst the infertiles, the further analysis illustrated in this Example will have an important diagnostic value, as regards the counselling and treatment to be offered.

DNA is prepared from the same sources and using the same methods as indicated under Example 1 (above). Long-extension PCR is carried out using a series of primer pairs flanking blocks of exons of the *POLG* gene cre-

ART 34 AMU

ating products that include the entire coding region of the gene, the 5' and 3' untranslated segments of the *POLG* mRNA, the proximal promoter of the gene, and all intron/exon boundaries. Oligonucleotide primers are based on the publicly available sequence of the *POLG* gene (deposited in the Genbank database as accession number AC005317), and sourced from companies such as indicated under Example 1. In this specific example the relevant segments of the *POLG* gene are amplified initially as 3 large PCR products, although many other strategies are equivalent, based on other combinations of primers according to the database sequence. LX-PCR is carried out with a standard reagent kit (e.g. Boehringer Mannheim Extend DNA Polymerase) under manufacturer's recommended conditions or using equivalent materials sourced elsewhere. PCR products are analysed by agarose gel electrophoresis and purified from agarose gels by standard, spin-column methods, e.g. using kits available from Qiagen or similar manufacturers. A total of 52 sequencing primers are also required (one in each direction for the 21 short exons and boundaries, two in each direction to cover the longer exon 23, and three in each direction to cover the longest exon, exon 2, in which the CAG repeat lies, presenting additional difficulties. The 20 bp sequences of these correspond with intronic sequences located approximately 30 bp up- and downstream of the various intron-exon boundaries, based on the database-deposited gene sequence. In addition, internal exonic sequencing primers (one for each strand) are required for 20 bp regions in the middle of exon 23 and exon 2, as well as 20 bp on either side of the CAG repeat (one strand only, in each case, reading towards the repeat).

Fluorescent DNA sequencing is carried out using a standard dye-terminator reagent kit (e.g. PerkinElmer Big Dye) in thermal cycling reactions using the long PCR products as template and each sequencing primer as appropriate under the kit manufacturer's recommended conditions. Sequencing reaction products are analyzed by gel or capillary electrophoresis, on a suitable electrophoresis/fluorescent analysis instrument, e.g. ABI 310 Genetic Analyzer (PerkinElmer), using the manufacturer's data collection and analysis software.

DNA sequences are carefully examined for evidence of 3 types of detectable heterozygosity, which manifest differently on the sequence traces, as follows. (a) A heterozygous point mutation manifests as a specific ambiguity localized to one nucleotide pair and detectable on both strands in a congruent

manner (i.e. the specific ambiguity on one strand is found as the exactly complementary ambiguity on the other). (b) A heterozygous deletion or insertion of one or more nucleotides in a localized region manifests as a break-point between a sequence that is readable (unambiguous) and a sequence that is totally unreadable (ambiguous at virtually every position), with the exact location and size of the deletion or insertion inferred by the positions at which ambiguity commences when read on the two strands. (c) A large heterozygous deletion or insertion less than 10 kb in size, with both break-points located within the gene, is evident from heterogeneity in the product sizes in long PCR, with a need to sequence the two alternate products independently to infer the nature and location of the re-arrangement.

A heterozygous deletion or insertion longer than 10 kb or with only one break-point located within the gene does not necessarily manifest in a simple manner by such methods, but can be detected by the use of restriction mapping combined with Southern blotting, or by so-called one-sided PCR methods, in which the flanking regions of a given sequence in genomic DNA are characterized by restriction digestion, dilution, religation to form circles, and PCR using two adjacent, outwardly oriented primers.

Where evidence of a heterozygous mutation is obtained, some form of haplotype analysis is still required to confirm that the CAG repeat-length mutation and the additional heterozygous mutation are on different copies of the gene. This requires a combination of standard mutation detection methods, such as allele-specific PCR, or restriction fragment length polymorphism applied over a considerable length of genomic DNA, involving, for example, long-extension PCR or Southern blotting or a combination of such techniques.

The implications of the results from this much more exhaustive test are similar to those outlined under example 1. Assignment of a mutation may not be straightforward, but *POLG* mutations that cause changes of reading frame, that destroy splice sites or create new ones, that generate a stop codon, that alter a highly conserved amino acid or that delete or interrupt a significant region of coding sequence are unquestionably of pathological significance, if combined with CAG repeat-length mutation in the other copy of the gene.

Detection of a second, clearly pathological mutation in such an individual, outside of the CAG repeat, would confirm that his infertility is of essentially the same kind as those already discussed under example 1, with similar

implications for counselling and treatment.

Example 3

Application of the invention to population-based screening for genetic predisposition to infertility

5 This example describes the way in which the invention is to be applied in the context of genetic screening of the population. It is assumed that this application will respect privacy, plus any relevant legislation in force in different jurisdictions. Its goal is to enable people to make informed choices about their reproductive life without prescribing to them any particular course
10 of action. The possibility for a male to know, in advance, that he will suffer infertility at reproductive age, empowers both him and his partner in a way that other kinds of clinical testing do not, given that they are typically applied long after the problem has manifested and usually too late for its consequences to be completely corrected or managed. This application could be placed in the
15 context of a programme of voluntary genetic testing applied in infancy, or at any age, being offered as one of a large number of tests for genetic disorders. It could also be in the context of a confidential advisory service or even, eventually, a self-test kit. The specific example given is in the context of a voluntary public health programme focused on the specific question of genetic
20 predisposition to infertility and offered in early adolescence.

A defined population of young males (e.g. all those reaching their 17th birthday in a given year in a given locality) are contacted via family doctors, educational institutions or a population registry and asked whether they wish to participate voluntarily in the screening programme under conditions of
25 total confidentiality. The benefits of choosing to do so, plus the predictive limitations of the test, are fully explained to all enabling them to make an informed choice about their participation. Buccal smears (mouthwash samples) are collected from those agreeing to take the test, and DNA is extracted using similar methods as outlined under example 1. *POLG* genotyping is carried out using
30 the same techniques as outlined in examples 1 and 2 above. The results of the test are communicated to all volunteers on a confidential basis, with more specific counselling offered to anyone who requests it.

The test results and their implications are clear: those found to be homozygous for loss of the wild-type *POLG* repeat-length allele, or to be compound heterozygotes with one copy of the gene mutated at the CAG repeat
35 and one copy carrying a clearly pathological mutation elsewhere in the gene,

are advised that prior genetic surveys indicate that they will suffer from a fertility problem, and that if they wish to have children they should consult an infertility clinic at the appropriate time to arrange for assisted reproduction as already described under example 1. Those found to carry at least one wild-type
5 copy of the gene are advised that one common, genetic cause of male infertility has been excluded, but that this does not necessarily mean that they will be free of fertility problems, since there are other genetic and environmental causes that account for a large fraction of fertility problems. Hence they should be aware of the relevant services available in their locality, and advised to
10 seek specific advice if they become aware of a fertility problem in the future.

Obviously, the value of the test described in this example will be greatly enhanced, if combined in the future with tests for other genetic predispositions to male infertility, as these become apparent. This will strengthen the predictive value of the test, although even those in whom all genetic causes of
15 male infertility have been excluded must be made aware that their partner may also suffer fertility problems independently, and that genetics cannot explain everything.

CLAIMS

1. A method for the diagnosis of male infertility, **character-**
ized by detecting the presence or absence of a mutation or mutations in the
POLG gene encoding the catalytic subunit of mitochondrial DNA polymerase
5 in a biological sample.

2. A method for population-based screening for genetic predisposi-
tion to male infertility, **characterized** by detecting the presence or ab-
sence of a mutation or mutations in the *POLG* gene encoding the catalytic
subunit of mitochondrial DNA polymerase in a biological sample.

10 3. A method of claim 1 or 2, **characterized** in that the muta-
tion or mutations are located in the trinucleotide (CAG) microsatellite repeat of
the *POLG* gene.

4. A method of claim 3, **characterized** in that the mutation
or mutations are located in both alleles of the *POLG* gene in the trinucleotide
15 (CAG) microsatellite repeat of the *POLG* gene.

5. A method of claim 1 or 2, **characterized** in that the muta-
tion or mutations are located in or near a coding region of the *POLG* gene.

6. A method of claim 1 or 2, **characterized** in that one muta-
tion or mutations are located in one allele of the *POLG* gene in the trinucleo-
20 tide (CAG) microsatellite repeat and another mutation or other mutations in the
other allele of the mutant *POLG* gene in or near a coding region of the gene.

7. A method of any one of claims 1 to 6, **characterized** in
that the detection of the mutation is performed using a gene-technological
method.

25 8. A method of claim 7, **characterized** in that the detection
of the mutation or mutations is performed using the polymerase chain reaction
(PCR) or other thermal cycler-based DNA synthetic techniques, molecular
cloning in a plasmid or other suitable vector, detection of length variants in a
DNA sample by agarose or polyacrylamide gel electrophoresis, gel or capillary
30 electrophoresis and analysis of products tagged with a fluorescent or other la-
bel incorporated into the DNA, DNA sequence determination and any hetero-
duplex-based or similar methods for detecting base mismatches or length
variants.

9. A method of any one of claims 1 to 6, **characterized** in
35 that the detection of the mutation or mutations is performed using an immu-

nological method, such as a Western analysis, immunohistology or immunoassay, for characterization of a mutant gene or gene product.

10. A method of claim 9, **characterized** in that the detection of mutation or mutations is performed using immunohistology.

5 11. A use of a mutant form of the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase for the diagnosis or prediction of male infertility.

12. A use of a mutant form of the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase as a diagnostic agent.

10 13. A diagnostic kit, **characterized** in that it comprises reagents capable of identifying the presence or absence of a mutation or mutations in the *POLG* gene encoding the catalytic subunit of mitochondrial DNA polymerase.

15 14. A use of the *POLG* gene as an indicator of other pathological conditions associated with or related to male infertility, including those manifesting in women.





FIG. 1



37 C.F.R. 1.63
**INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Diagnostic and screening method for male infertility

the specification of which (check applicable box(es)):

☐ is attached hereto
☐ was filed on _____ as U.S. Application Serial No. _____ (Atty Dkt.)
☒ was filed as PCT International application No. PCT/FI00/00140 on 22 February 2000
and (if applicable to U.S. or PCT application) was amended on 9 May 2000

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
990380	Finland	22 February 1999

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed
--------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
Error! Reference source not found.		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoads, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s)...

1. Inventor's Signature: [Signature] Date: 14/11/01
Inventor: Howard TRAVOR JACOBS British
(first) (last) (citizenship)
Residence: (city) TAMPERE FI (state/country) FINLAND
Mailing Address: NASILINNANKATU 33A D I K
(Zip Code) FIN-33200

2. Inventor's Signature: [Signature] Date: 14.11.2001
Inventor: Anja TUULIKKI ROVIO Finnish
(first) (last) (citizenship)
Residence: (city) KANGASALA FI (state/country) FINLAND
Mailing Address: NOORIMARKKINKUJA 4
(Zip Code) FIN-36200

☐ See attached sheet(s) for additional inventor(s) information!!



13 Rec'd PCT/PTO 04 DEC 2001

09/913954

SEQUENCE LISTING

<110> Jacobs, Howard
Rovio, Anja

<120> Diagnostic and Screening Method

<130> 227-142 / 2980578US

<140> 09/913,954
<141> 2001-08-21

<150> PCT/FI00/00140
<151> 2000-02-22

<150> FI 990380
<151> 1999-02-22

<160> 5

<170> PatentIn version 3.1

<210> 1
<211> 4440
<212> DNA
<213> Human

<400> 1
gcggaccggc cgggtggagg ccacacgcta ccccgaggct gcgtaggccg cgccaagggg 60
gacgccgtgc cgtgggcctg gggtcggggg agcagcagac cgggaagcac cgtgaggacc 120
gaggatttgg ggtggaaggc aggcattggc aaaccattt cactgacagg agagcagaga 180
caggacgtgt ctctctccac gtcttccagc cagtaaaaga agccaagctg gagcccaaag 240
ccaggtgttc tgactcccag cgtggggggtc cctgcaccaa ccatgagccg cctgctctgg 300
aggaaggtgg cgggcgccac cgtcggggcca gggccgggtc cagctccggg gcgctgggtc 360
tccagctccg tccccgcgtc cgaccccagc gacgggcagc ggccggcgga gcagcagcag 420
cagcagcagc agcagcagca acagcagcct cagcagccgc aagtgcctatc ctcggagggc 480
gggcagctgc ggcacaacct attggacatc cagatgctct cgagagggct gcacgagcaa 540
atcttcggggc aaggagggga gatgcctggc gaggccggcg tgcgccgcag cgtcgagcac 600
ctgcagaagc acgggctctg ggggcagcca gccgtgccct tgcccagcgt ggagctgcgc 660
ctgccgcccc tctacgggga caacctggac cagcacttcc gcctcctggc ccagaagcag 720
agcctgccct acctggaggc ggccaacttg ctgttgacag cccagctgcc cccgaagccc 780
ccggcttggg cctgggcgga gggctggacc cggtagcgcc ccgaggggga ggccgtaccc 840
gtggccatcc ccgaggagcg gggcctggtg ttcgacgtgg aggtctgctt ggcagaggga 900
acttgcccca cattggcggt ggccatatcc cctcggcct ggtattcctg gtgcagccag 960
cggctggtgg aagagcggtta ctcttgacc agccagctgt cgccggctga cctcatcccc 1020

ctggaggtcc	ctactggtgc	cagcagcccc	acccagagag	actggcagga	gcagttagtg	1080
gtggggcaca	atgtttcctt	tgaccgagct	catatcaggg	agcagtacct	gatccagggg	1140
tcccgcagtc	gtttcctgga	caccatgagc	atgcacatgg	ccatctcagg	gctaagcagc	1200
ttccagcgca	gtctgtggat	agcagccaag	cagggcaaac	acaaggtcca	gccccccaca	1260
aagcaaggcc	agaagtccca	gaggaaagcc	agaagaggcc	cagcgatctc	atcctggggac	1320
tggctggaca	tcagcagtgt	caacagtctg	gcagaggtgc	acagacttta	tgtagggggg	1380
cctcccttag	agaaggagcc	tcgagaactg	tttgtgaagg	gcacatgaa	ggacattcgt	1440
gagaacttcc	aggacctgat	gcagtactgt	gcccaggagc	tgtggggccac	ccatgaggtt	1500
ttccagcagc	agctaccgct	cttcttggag	aggtgtcccc	accagtgc	tctggccggc	1560
atgctggaga	tgggtgtctc	ctacctgcct	gtcaaccaga	actgggagcg	ttacctggca	1620
gaggcacagg	gcacttatga	ggagctccag	cgggagatga	agaagtcgtt	gatggatctg	1680
gccaatgatg	cctgccagct	gctctcagga	gagaggtaca	aagaagacct	ctggctctgg	1740
gacctggagt	gggacctgca	agaatttaag	cagaagaaag	ctaagaaggt	gaagaaggaa	1800
ccagccacag	ccagcaagtt	gcccacagag	ggggctgggg	cccctggtga	tcccatggat	1860
caggaagacc	tcggccccctg	cagtgaggag	gaggagtctc	aacaagatgt	catggccccg	1920
gctgcttgc	agaagctgaa	ggggaccaca	gagctcctgc	ccaagcggcc	ccagcacctt	1980
cctggacacc	ctggatggta	ccggaagctc	tgcccccgcc	tagacgacct	tgcattggacc	2040
ccgggccccca	gcctcctcag	cctgcagatg	cgggtcacac	ctaaactcat	ggcacttacc	2100
tgggatggct	tccctctgca	ctactcagag	cgtcatggct	ggggctactt	ggtgcctggg	2160
cggcgggaca	acctggccaa	gctgccgaca	ggtaccacct	tggagtgcgc	tgggggtggc	2220
tgcccctaca	gagccatcga	gtccctgtac	aggaagcact	gtctcgaaca	ggggaagcag	2280
cagctgatgc	cccaggaggc	cggcctggcg	gaggagtctc	tgctcactga	caatagtgcc	2340
atatggcaaa	cggtagaaga	actggattac	ttagaagtgg	aggctgaggc	caagatggag	2400
aacttgcgag	ctgcagtgcc	aggtcaacct	ctagctctga	ctgcccgtgg	tggccccaag	2460
gacaccagc	ccagctatca	ccatggcaat	ggaccttaca	acgacgtgga	catccctggc	2520
tgctggtttt	tcaagctgcc	tcacaaggat	ggtaatatgt	gtaatgtggg	aagccccctt	2580
gccaaggact	tcctgccccaa	gatggaggat	ggcaccctgc	aggctggccc	aggaggtgcc	2640
agtggggccc	gtgctctgga	aatcaacaaa	atgatttctt	tctggaggaa	cgcccataaa	2700
cgtatcagct	cccagatggg	ggtgtggctg	cccaggctcag	ctctgccccg	tgctgtgatc	2760
aggcaccg	actatgatga	ggaaggcctc	tatggggcca	tcctgccccca	agtgggtgact	2820
gccggcacca	tcactcgccg	ggctgtggag	cccacatggc	tcaccgccag	caatgccccg	2880

cctgaccgag	taggcagtga	gttgaaagcc	atggtgcagg	ccccacctgg	ctacacccctt	2940
gtgggtgctg	atgtggactc	ccaagagctg	tggattgcag	ctgtgcttgg	agacgcccac	3000
tttgccggca	tgcattggctg	cacagccttt	gggtggatga	cactgcaggg	caggaagagc	3060
aggggcactg	atctacacag	taagacagcc	actactgtgg	gcattcagccg	tgagcatgcc	3120
aaaatcttca	actacggccg	catctatgg	gctgggcagc	cctttgctga	gcgcttacta	3180
atgcagttta	accaccggct	cacacagcag	gaggcagctg	agaaggccca	gcagatgtac	3240
gctgccacca	agggcctccg	ctggatatcg	ctgtcggatg	agggcgagtg	gctggtgagg	3300
gagttgaacc	tcccagtggga	caggactgag	ggtggctgga	tttccttgca	ggatctgcgc	3360
aaggtccaga	gagaaactgc	aaggaagtca	cagtggaaga	agtgggaggt	ggttgctgaa	3420
cgggcatgga	aggggggcac	agagtcagaa	atgttcaata	agcttgagag	cattgctacg	3480
tctgacatac	cacgtacccc	ggtgctgggc	tgtgcattca	gccgagccct	ggagccctcg	3540
gctgtccagg	aagagtttat	gaccagccgt	gtgaattggg	tggtacagag	ctctgctggt	3600
gactacttac	acctcatgct	tgtggccatg	aagtggctgt	ttgaagagtt	tgccatagat	3660
gggcgcttct	gcattcagcat	ccattgacgag	gttcgctacc	tgggtgcggga	ggaggaccgc	3720
taccgcgctg	ccctggcctt	gcagatcacc	aacctcttga	ccaggtgcat	gtttgcctac	3780
aagctgggtc	tgaatgactt	gccccagtca	gtcgcttttt	tcagtgcagt	cgatattgac	3840
cgggtgcctca	ggaagggaagt	gaccatggat	tgtaaaaccc	cttccaaccc	aactgggatg	3900
gaaaggagat	acgggattcc	ccagggtgaa	gcgctggata	tttaccagat	aattgaactc	3960
accaaaggct	ccttgaaaaa	acgaagccag	cctggaccat	agcactgcct	ggaggctctg	4020
tatttgctcc	cgtggagctt	catcggggtg	gtgcaggctc	ccaaactcag	gctttcagct	4080
gtgctttttg	caaaagggtc	tgctaaggc	cagccatttt	tcagtagcag	gacctgcca	4140
gaagattcct	tctaactgaa	ggtgcagttg	aattcagtg	gttcagaacc	aagatgcca	4200
catcgggtgt	gactacagga	caaggggcat	tgttgcttgt	tgggtaaaaa	tgaagcagaa	4260
gccccaaagt	tcacattaac	tcaggcattt	catttatatt	ttccttttct	tcttggctgg	4320
ttctttgttc	tgtcccccac	gctctgatgc	agtgccttag	aaggggaaag	aattaatgct	4380
ctaacgtgat	aaacctgctc	caaggcagtg	gaaataaaaa	gaaggaaaaa	aaagaaaaaa	4440

```
<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> primer
```

 $\langle 400 \rangle$ 2

ccagctccgt ccccgcgtaa gacc

24

<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 3
gctgccccgcc ctccgaggat agcac

25

<210> 4
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 4
ctctcgagag catctggatg tccaatc

27


<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 5
ctcgtgcagc cctctcgaga gcat

24

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☒ Scanned copy is best available. Page #1 of Preliminary
Amendment was torn.